Andrea L Roberts1, Laura D Kubzansky2,3, Susan Malspeis4, Candace H Feldman4, Karen H Costenbader4. 1. Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 2. Department of Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 3. Lee Kum Sheung Center for Health and Happiness, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 4. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
Importance: It has long been hypothesized that depression may increase the risk of developing autoimmune disease; however, rigorous empirical evidence is sparse. Objective: To evaluate whether an association exists between depression and risk of incident systemic lupus erythematosus (SLE), a paradigmatic, systemic autoimmune disease. Design, Setting, and Participants: This 20-year prospective, longitudinal cohort study evaluated data collected from 2 cohorts of women participating in the Nurses' Health Study (1996-2012) and the Nurses' Health Study II (1993-2013). Data analyses were conducted from August 2017 to May 2018. Main Outcomes and Measures: Incident SLE with 4 or more American College of Rheumatology criteria was ascertained by self-report and confirmed by medical record review. Depression was assessed repeatedly throughout follow-up according to whether women reported having received a clinician's diagnosis of depression, regular antidepressant use, or a score of less than 60 on the 5-item Mental Health Inventory (MHI-5). Whether longitudinally assessed health risk factors (eg, cigarette smoking, body mass index, oral contraceptive use, menopause or postmenopausal hormone use, alcohol use, exercise, or diet) accounted for increased SLE risk among women with vs without depression was examined. Cox proportional hazards regression models were used to estimate risk of SLE. In addition, the association of depression lagged by 4 years, and depression status at baseline with incident SLE throughout follow-up was assessed. Results: Data from 194 483 women (28-93 years of age; 93% white) were included. During 20 years of follow-up, 145 cases of SLE occurred. Compared with women with no depression, women with a history of depression had a subsequent increased risk of SLE (HR, 2.67; 95% CI, 1.91-3.75; P < .001). Adjustment for body mass index, cigarette smoking, and oral contraception and postmenopausal hormone use slightly attenuated associations (adjusted HR, 2.45; 95% CI, 1.74-3.45; P < .001). The SLE risk was elevated with each of the 3 following depression indicators modeled separately: clinician's diagnosis of depression (HR, 2.19; 95% CI, 1.29-3.71), antidepressant use (HR, 2.80; 95% CI, 1.94-4.05), and MHI-5 scores indicating depressed mood (HR, 1.70; 95% CI, 1.18-2.44). Associations remained strong when depression status was lagged by 4 years with respect to the outcome (HR, 1.99; 95% CI, 1.32-3.00) and when depression status at baseline was used as the exposure (HR, 2.28; 95% CI, 1.54-3.37). Conclusions and Relevance: This study contributes to increasing evidence that depression may be associated with increased risk of SLE and suggests that the association is not fully explained by measured health factors or behaviors.
Importance: It has long been hypothesized that depression may increase the risk of developing autoimmune disease; however, rigorous empirical evidence is sparse. Objective: To evaluate whether an association exists between depression and risk of incident systemic lupus erythematosus (SLE), a paradigmatic, systemic autoimmune disease. Design, Setting, and Participants: This 20-year prospective, longitudinal cohort study evaluated data collected from 2 cohorts of women participating in the Nurses' Health Study (1996-2012) and the Nurses' Health Study II (1993-2013). Data analyses were conducted from August 2017 to May 2018. Main Outcomes and Measures: Incident SLE with 4 or more American College of Rheumatology criteria was ascertained by self-report and confirmed by medical record review. Depression was assessed repeatedly throughout follow-up according to whether women reported having received a clinician's diagnosis of depression, regular antidepressant use, or a score of less than 60 on the 5-item Mental Health Inventory (MHI-5). Whether longitudinally assessed health risk factors (eg, cigarette smoking, body mass index, oral contraceptive use, menopause or postmenopausal hormone use, alcohol use, exercise, or diet) accounted for increased SLE risk among women with vs without depression was examined. Cox proportional hazards regression models were used to estimate risk of SLE. In addition, the association of depression lagged by 4 years, and depression status at baseline with incident SLE throughout follow-up was assessed. Results: Data from 194 483 women (28-93 years of age; 93% white) were included. During 20 years of follow-up, 145 cases of SLE occurred. Compared with women with no depression, women with a history of depression had a subsequent increased risk of SLE (HR, 2.67; 95% CI, 1.91-3.75; P < .001). Adjustment for body mass index, cigarette smoking, and oral contraception and postmenopausal hormone use slightly attenuated associations (adjusted HR, 2.45; 95% CI, 1.74-3.45; P < .001). The SLE risk was elevated with each of the 3 following depression indicators modeled separately: clinician's diagnosis of depression (HR, 2.19; 95% CI, 1.29-3.71), antidepressant use (HR, 2.80; 95% CI, 1.94-4.05), and MHI-5 scores indicating depressed mood (HR, 1.70; 95% CI, 1.18-2.44). Associations remained strong when depression status was lagged by 4 years with respect to the outcome (HR, 1.99; 95% CI, 1.32-3.00) and when depression status at baseline was used as the exposure (HR, 2.28; 95% CI, 1.54-3.37). Conclusions and Relevance: This study contributes to increasing evidence that depression may be associated with increased risk of SLE and suggests that the association is not fully explained by measured health factors or behaviors.
Authors: Melissa E Munroe; Kendra A Young; Diane L Kamen; Joel M Guthridge; Timothy B Niewold; Karen H Costenbader; Michael H Weisman; Mariko L Ishimori; Daniel J Wallace; Gary S Gilkeson; David R Karp; John B Harley; Jill M Norris; Judith A James Journal: Arthritis Rheumatol Date: 2017-03 Impact factor: 10.995
Authors: Ashwin N Ananthakrishnan; Hamed Khalili; An Pan; Leslie M Higuchi; Punyanganie de Silva; James M Richter; Charles S Fuchs; Andrew T Chan Journal: Clin Gastroenterol Hepatol Date: 2012-08-31 Impact factor: 11.382
Authors: Candace H Feldman; Susan Malspeis; Cianna Leatherwood; Laura Kubzansky; Karen H Costenbader; Andrea L Roberts Journal: J Rheumatol Date: 2019-05-15 Impact factor: 4.666
Authors: John Abel Engh; Thor Ueland; Ingrid Agartz; Dimitrios Andreou; Pål Aukrust; Birgitte Boye; Erlend Bøen; Ole Kristian Drange; Torbjørn Elvsåshagen; Sigrun Hope; Margrethe Collier Høegh; Inge Joa; Erik Johnsen; Rune Andreas Kroken; Trine Vik Lagerberg; Tove Lekva; Ulrik Fredrik Malt; Ingrid Melle; Gunnar Morken; Terje Nærland; Vidar Martin Steen; Kirsten Wedervang-Resell; Melissa Auten Weibell; Lars Tjelta Westlye; Srdjan Djurovic; Nils Eiel Steen; Ole Andreas Andreassen Journal: Schizophr Bull Date: 2022-01-21 Impact factor: 7.348
Authors: Albeliz Santiago-Colón; Robert Daniels; Dori Reissman; Kristi Anderson; Geoffrey Calvert; Alexis Caplan; Tania Carreón; Alan Katruska; Travis Kubale; Ruiling Liu; Rhonda Nembhard; W Allen Robison; James Yiin; John Howard Journal: Int J Environ Res Public Health Date: 2020-10-06 Impact factor: 3.390
Authors: Jeffrey A Sparks; Susan Malspeis; Jill Hahn; Jiaqi Wang; Andrea L Roberts; Laura D Kubzansky; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794